Recently, a HIV drug has received green signal from the US Food and Drug Administration. The drug, known as Stribild, which is said to act as a complete treatment for HIV, has been prepared by using two existing pills and two other new pills.

The US health regulators were quick in pointing that the drug is meant for people who have yet to start medication for HIV and have never taken any kind of treatment for the same in the past.

Edward Cox, who is positioned as the head of Office of Antimicrobial Products department in the FDA, was of the view that the new pill will simplify the HIV treatment. It has been developed by Gilead Sciences, a company bases in California.

"Therapies that address the individual needs of patients are critical to enhancing adherence and increasing the potential for treatment success", said John Martin, who is the head of Gilead Sciences.

Though the drug has been approved for the US market, the company is still seeking approval for the same in other countries, like Australia, Canada and the EU.

Cox said the drug packet will bear the warning signal that it can cause sideeffects, which can range from mild to moderate level.